Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.

doi:10.1016/j.lungcan.2018.05.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2018

Wang Hanping, Zhang Li, Hu Pei, Zheng Xin, Si Xiaoyan, Zhang Xiaotong, Wang Mengzhao

Abstract excerpt

BACKGROUND: Avitinib is an oral, potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for the EGFR T790 M mutation. We report the safety, intra-/extracranial efficacy, and the blood-brain barrier (BBB) penetration rate of avitinib (NCT02330367). METHODS: Non-small cell lung cancer (NSCLC) patients with the EGFR T790 M mutation were orally administered avitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Blood-Brain Barrier
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Pyrimidines

Share to Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 30032814
DOI: 10.1016/j.lungcan.2018.05.010

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.